News

Our News

HTL, winner of the special jury prize at the CCI France International Trophy

June 27, 2022

The 3rd edition of the CCI France International Trophies was held on June 27 in Paris at the Pavillon d'Armenonville, in the presence of Franck RIESTER, former Minister Delegate to the Minister of Europe and Foreign Affairs, in charge of Foreign Trade and Attractiveness.

The objective of the event? To promote French success stories on the international scene!

Read more : www.ccifrance-international.org/

Copyright : Xavier Renauld – CCI France International.

PRESS RELEASE: HTL accelerates its development strategy with the appointment of François Fournier as CEO from September 1st, 2022

June 8, 2022

An experienced healthcare executive and expert in HTL’s therapeutic areas, in particular dermatology and medical aesthetics, François Fournier brings more than 20 years’ experience in corporate strategy, business execution, and international leadership.
Read more below.

English | Français

IMCAS World Congress 2022... Back in Paris!

May 20, 2022

HTL will be exhibiting at the 23rd IMCAS World Congress 2022 in Paris from 3 to 5 June. Our team will be there to network with global and local players in the fields of dermatology, plastic surgery and aesthetic science. Meet us on our booth n°P336 on level 3. We will be delighted to discuss opportunities in medical device innovation brought by our biopolymer platform.
More about IMCAS at www.imcas.com

BIO International Convention 2022: connecting with the biotech ecosystem

May 17, 2022

The HTL team will be present at the Bio International Convention from 13 to 16 June in San Diego. The Bio is the ultimate event to network with the biotech innovation ecosystem. It brings together 15,000+ life science leaders and innovators in fields such as drug discovery, biomanufacturing, genomics, nanotechnology, and cell therapy. Our team will be there to discuss opportunities within our HTL incubator and biopolymer platform. We are looking for projects in various pharmaceutical and medical fields: aesthetics, dermatology, ophthalmology, rheumatology, regenerative medicine, prosthetics and implants, oncology, urology… Meet us at Bio!

HTL is now ISO 14001 certified

April 14, 2022

We are delighted to announce that the management system of HTL is now certified conform to the ISO 14001:2015 Environmental Management System standard. We use ISO 14001:2015 to manage our environmental responsibilities in line with the environmental pillar of our CSR program. Learn more about our commitments and initiatives.

PRESS RELEASE: HTL announces its incubator's equity investment in GelMEDIX, an early-stage biotech aiming at revolutionizing ocular and regenerative therapies

March 10, 2022

This partnership represents the first equity investment of the incubator created by HTL to accelerate the development of innovative treatments using biopolymers in therapeutic areas with unmet medical needs. HTL will provide financial, industrial and scientific support to GelMEDIX to facilitate the development of next generation ocular and regenerative therapies based on its proprietary hydrogel platform. This platform enables the delivery of therapeutics from small molecules to cell and gene therapies.

Read more below

English | Français

PRESS RELEASE: HTL announces Montagu as new investor alongside its historical shareholders, Naxicap and Téthys Invest

February 28, 2022

HTL announces that Montagu, a leading private equity firm, has acquired a majority stake of HTL previously held by Bridgepoint. The other minority shareholders, Naxicap and Téthys Invest, will keep their shares in the company. The arrival of this new shareholder symbolizes the international success of a company that has become the world leader in the development and production of pharmaceutical grade biopolymers.

Read more below.

English |
Français

HTL sponsors the 6th TERMIS World Congress

November 12, 2021

HTL is proud to sponsor the 6th TERMIS World Congress that will take place online on 15 to 19 November 2021. This congress brings together researchers, scientists, clinicians, trainees and students from both academia and industry to discuss critical developments in the fields of Tissue Engineering and Regenerative Medicine.
Click here to learn more about TERMIS.

HTL 4: marketing authorization issued by the EDQM

November 9, 2021

The EDQM (European Directorate for the Quality of Medicines and Healthcare), which issues certificates of conformity (CEP) verifying the conformity of substances used for the manufacture of medicines to the standards of the European pharmacopoeia, has just authorized the addition of the HTL4 line to our CEP. HTL can now market the Medical Grade Hyaluronic Acid batches produced on this manufacturing line.

Meet the HTL team at the CPhI Worldwide 2021 from 9 to 11 November in Milan

November 8, 2021

Finally, CPhI is live! the HTL team is ready to welcome you at the global CPhI exhibition in Milan, Italy, at the HTL booth - Number F13, Hall 14 (API area). This will be an opportunity to discuss value creation opportunities with biopolymers for medical applications. The team is also available for networking at the online event until November 19. Click here to connect.

PRESS RELEASE: HTL launches a new, cutting-edge bioproduction unit for pharmaceutical-grade biopolymers

September 30, 2021

Representing an investment of more than 50 million euros, this new unit dedicated to the bioproduction of pharmaceutical-grade hyaluronic acid represents a pivotal stage in the development of HTL and the largest investment ever made in the world for a biopolymer production unit. It will enable HTL to become the largest producer of pharmaceutical-grade hyaluronic acid in the world and accelerate its international development.

Read more below.

English | Français

PRESS RELEASE: BMG Pharma and HTL sign a development agreement to manufacture BMG’s new biopolymer based on the Hyaluromimethic® Technology

September 14, 2021

The agreement between BMG Pharma and HTL will allow BMG Pharma to develop and commercialize injectable products with Sodium Hyaluronate Lipoate Formate (SHLF). BMG Pharma through its patented Hyaluromimethic® Technology works on SHLF to develop solutions in aesthetic dermatology, ophthalmology, and arthrosis. Thanks to this agreement, BMG Pharma will globally develop new formulations of its injectable products, always with high levels of quality, stability, and safety standards.

Read more below.

English | Français

PRESS RELEASE: Eirion Therapeutics Announces Strategic Agreement for HTL Biotechnology to Become Eirion’s Exclusive Botulinum API Manufacturer

September 8, 2021

Eirion Therapeutics, Inc., an aesthetic dermatology company headquartered in Woburn, Massachusetts, announced that HTL Biotechnology, the worldwide leader in biotechnology solutions using hyaluronic acid and other biopolymers, will become Eirion’s exclusive botulinum active pharmaceutical ingredient (API) manufacturer.

Read more below.

English | Français

HTL at Bio International 2021

June 9, 2021

HTL is thrilled to participate to Bio International 2021, the world’s largest business convention dedicated to biotech and pharma. Together with Business France and French Healthcare, we will be next week on the One-on-One partnering platform. We are looking forward to identifying and developing new partnerships!

New offices in Singapore

June 8, 2021

HTL is pleased to announce the opening of our new offices in Singapore. This announcement is a natural progression of our continued expansion in Asia. The new offices will allow us to serve our global clientele and partners more effectively and efficiently. Our products are used by market leaders worldwide, and we are continuously creating global and local partnerships with major research players. This is yet another milestone in our journey towards the next breakthrough in human health.

For more information, give us a call or use our contact form.

EcoVadis Sustainability rating: HTL receives Gold Medal

June 4, 2021

HTL has obtained a gold medal for its first EcoVadis sustainability rating. This places us in the top 5% of companies evaluated in our industry sector. We would like to thank all the employees who are making this success possible and work on improving our environmental, social and societal impacts. This achievement encourages us to continue measure and improve our CSR performance. Let’s go beyond, together!

Click here to view the certificate.

PRESS RELEASE: HTL Biotechnology and Terasaki Institute for Biomedical Innovation announce Memorandum of Understanding for research in translational biomaterials

May 10, 2021

HTL, the world leader in biotechnology solutions based on hyaluronic acid (HA) and other biopolymers and the Terasaki Institute for Biomedical Innovation (TIBI), a US-based research institute at the frontier of personalized and precision medicine, announced their Memorandum of Understanding (MOU) to explore the creation of a joint research program. This program will focus on biomaterials for translational programs combining TIBI’s microneedle and bioprinting technologies with HTL’s expertise in biopolymers for aesthetics, dermatology, ophthalmology, rheumatology, tissue engineering and drug delivery applications.

Read more below.

English | Français

PRESS RELEASE: HTL and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools

April 13, 2021

HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announce their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products.

The partnership provides academic research and pharmaceutical development laboratories expanded access to Good Manufacturing Practices (GMP)-grade, kit-packaged hyaluronic acid and glycosaminoglycan (GAG) products. By offering premium, clinical grade products to early-stage research investigators, the partnership seeks to bridge the gap between lab-based research, development and commercialization, and accelerate innovation worldwide.

Read more below.

English | Français | Deutsch

PRESS RELEASE: LabCom GELMECS, a new shared laboratory for biomaterials in regenerative medicine

December 10, 2020

HTL is engaged in the development of biomaterials for regenerative medicine by the creation of a shared laboratory with the RMeS (Regenerative Medicine and Skeleton) research unit: the GELMECS LabCom, based in Nantes, France. Its objective is to develop hydrogels for the pharmaceutical industry, tissue engineering and assisted cell therapy. These new biomaterials using silanized hyaluronic acid have demonstrated their pertinence in terms of interest and efficiency for the creation of injectable bone replacements and cement foams for bone regeneration.

Read more below.

English | Français

HTL sponsors the 11th World Biomaterials Congress - WBC 2020

December 2020

HTL is proud to sponsor WBC 2020 virtual, the 11th World Biomaterials Congress that will take place online from 11 to 15 December. This event connects an international audience of thousands of biomaterials professionals: researchers, academics, scientists and other representatives from biomedical companies. We are happy to highlight our Scientific Advisor Glenn Prestwich, who will be a keynote speaker at the Special Symposium « Hyaluronic Acid, a powerful biomedical tool » on December 12th. He will be discussing chemically modified Hyaluronic Acid for regenerative and reparative medicine. HTL will also be a virtual exhibitor at WBC, with the objective of developing and strengthening its academic partnerships. More information at https://virtual.wbc2020.org/

Lockdown: you can count on us

November 2020

Following the latest lockdown measures announced in different parts of the world, HTL would like to confirm that we are able to continue to deliver our products as usual and ensure our customer service. Do not hesitate to contact us. Together, we will continue to work for health and well-being. With the evolving health situation, our responsibility is to maintain continued vigilance. The health and safety of our employees and our community remains our priority. We continue to rigorously apply our enhanced protection system: spreading prevention measures, reorganized workstations, priority for teleworking, cancellation of all trips and visits, reinforced cleaning. Together, let's stay mobilized.

Meet HTL at CPhI Festival of Pharma 2020 from 12 to 16 October

October 2020

As CPhI Worldwide 2020 will take place online for the first time, the HTL team will be ready to join the global pharma industry and network online at the Festival of Pharma from 12 to 16 October. Our team will discuss business and innovation opportunities around biopolymer APIs and raw materials. Together, we continue to develop the potential of biopolymers of non-animal origin: Hyaluronic Acid, Heparosan, Chondroitin and more. Join us and achieve your business goals. Let’s stay connected! Click here to sign up for free

COVID-19: HTL is protecting the safety of its employees and its facility

March 2020

HTL is protecting the safety of its employees and its facility, in order to guarantee supply chain continuity for its clients. Click here to view the statement. Cliquez ici pour visualiser le point de situation.

We will update this status report as the situation develops. The HTL team is available to answer your questions or provide further information.

HTL is exhibiting at 22nd IMCAS World Congress

January 2020

HTL works with its clients in the aesthetics sector to take dermal filling and skin rejuvenation to the next level. HTL is exhibiting at the 22nd World Congress IMCAS 2020 in Paris. The International Master Course in Aging Science addresses Youth & Age in dermatology, plastic surgery and aesthetic science.

HTL invests in GMP manufacturing capacity to support the rapidly growing market of Hyaluronic Acid Medical Applications

October 2019

HTL invests in GMP manufacturing capacity to support the rapidly growing market of Hyaluronic Acid Medical Applications. HTL announces its investment in a state-of-the-art production facility that will multiply its injectable grade sodium hyaluronate production capacity by 2.5 by 2021. This new capacity represents a much-needed opening in a global market under high pressure.

HTL at CPhI Worldwide 2019

October 2019

As an API manufacturer, HTL will be exhibiting at the CPhI Worldwide exhibition in Frankfurt, from 5 to 7 November 2019 at stand 42G13 (Hall 4.2). Our team will be available to discuss value creation opportunities with biopolymers in the fields of dermatology, ophthalmology, rheumatology, along with urology, oncology, biomaterials and regenerative medicine. Stop by and come discuss your needs. We look forward to introducing you to our:

  • Hyaluronic Acid (Sodium Hyaluronate) of non-animal, natural origin, matching your specific demands
  • New GlycosAminoGlycans: Heparosan and Chondroitin
  • Functionalized derivatives of GlycosAminoGlycans, bringing new functionalities to your end products: improved stability, mechanical and biological properties

Come and join us at this leading show!

Press Release: HTL invests in GMP manufacturing capacity

October 2019

HTL invests in GMP manufacturing capacity to support the rapidly growing market of hyaluronic acid medical applications. Read more below.

English | Français